Lupin, Tenpoint Partner to Commercialize YUVEZZI in Europe

MUMBAI — Global pharmaceutical major Lupin Limited has entered into a strategic commercialization partnership with biotechnology firm Tenpoint Therapeutics, Ltd. to market YUVEZZI across the European Union, the United Kingdom, Switzerland, Norway, and Iceland. Announced in corporate regulatory filings, the agreement grants Lupin's specialty ophthalmology subsidiary, VISUfarma B.V., exclusive rights to register, distribute, and commercialize the once-daily presbyopia eye drop across key Western and Northern European territories.

Commercial Licensing Structure and Deal Value

Under the terms of the agreement, VISUfarma obtains exclusive operational authority to handle regulatory submissions, brand promotion, sales distribution, and market access for YUVEZZI across 31 European nations.

The financial structure encompasses:

• Strategic Investment: An upfront 20 million euro ($21.8 million) investment via a Simple Agreement for Future Equity (SAFE) instrument.

• Milestone Commitments: Up to 55 million euros in regulatory and commercial achievement milestones.

• Royalty Sharing: Tiered royalties payable on net product sales across the contracted European markets following commercial rollout.

The licensing rights leverage VISUfarma's existing ophthalmology distribution networks across Germany, the UK, France, Italy, Spain, and Nordic markets.

Clinical Profile of YUVEZZI Ophthalmic Solution

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) represents the first dual-agent, once-daily prescription eye drop developed to correct presbyopia—the age-related loss of near-vision focusing capability that affects adults over age 45.

The formulation utilizes a dual mechanism of action:

• Carbachol Component: Promotes pupil constriction (miosis), increasing the depth of field to restore sharp near visual acuity without distorting distance sight.

• Brimonidine Tartrate Component: Prevents excessive pupil dilation while mitigating ocular redness and preserving low-light visibility.

In pivotal Phase 3 clinical evaluations (BRIO I and BRIO II), the combination therapy demonstrated rapid onset within 30 minutes and sustained up to 8 to 10 hours of near-vision improvement with favorable tolerability and minimal adverse events. The therapy secured approval from the U.S. Food and Drug Administration (FDA) in January 2026, and a Marketing Authorization Application (MAA) has been submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Strategic Portfolio Expansion for Lupin

The partnership reinforces Lupin's transition toward high-margin, differentiated specialty pharmaceuticals. By licensing late-stage and commercial-ready branded biologics and specialty formulations, the Mumbai-based multinational diversifies beyond traditional generic medicines.

Presbyopia impacts hundreds of millions of individuals across Europe, where reading glasses and corrective surgeries have historically served as the primary clinical interventions. Bringing a non-surgical, self-administered topical solution to the European market provides Lupin’s European operations with an anchor asset in the cash-pay and prescription vision-care segment.

Official Sources Section

Transaction details, regulatory filings, and therapeutic specifications were sourced directly from statutory announcements published by Lupin Limited on the National Stock Exchange of India and the BSE Limited, corporate releases from Tenpoint Therapeutics, and regulatory notices from the Medicines and Healthcare products Regulatory Agency.

Quote Section

According to official corporate disclosures:

"Lupin's extensive commercial footprint across Europe and VISUfarma's specialized ophthalmology franchise make them the ideal commercialization partner. This partnership accelerates patient access to YUVEZZI across major European markets, delivering a non-invasive, daily topical treatment for adults managing presbyopia."

Why It Matters

Presbyopia is a progressive condition that affects nearly all adults over mid-life, creating significant daily inconvenience and productivity hurdles. Commercializing a dual-action prescription eye drop in Europe offers millions of aging patients an alternative to reading glasses and invasive lens replacement surgeries, establishing a modern standard of care in outpatient ophthalmology.

Key Facts at a Glance

• Partnership Entities: Lupin Limited (via subsidiary VISUfarma B.V.) and Tenpoint Therapeutics, Ltd.

• Licensed Drug: YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%).

• Therapeutic Indication: Treatment of adult presbyopia (age-related near-vision loss).

• Deal Consideration: Up to €75 million (€20M upfront equity investment + up to €55M in milestones) plus royalties.

• Licensed Territories: European Union, United Kingdom, Switzerland, Norway, and Iceland.

Frequently Asked Questions

What did Lupin and Tenpoint Therapeutics announce?

Lupin announced that its European subsidiary, VISUfarma, has entered into an exclusive partnership with Tenpoint Therapeutics to commercialize the presbyopia eye drop YUVEZZI across the EU, UK, Switzerland, Norway, and Iceland.

What is YUVEZZI and how does it work?

YUVEZZI is a once-daily, dual-agent prescription eye drop combining carbachol and brimonidine tartrate to constrict the pupil and improve near vision without compromising distance clarity.

What is the commercial value of the licensing agreement?

The total deal is valued at up to 75 million euros, comprising a 20 million euro upfront SAFE investment, up to 55 million euros in regulatory and commercial milestones, and royalties on net sales.

What is the regulatory status of YUVEZZI?

YUVEZZI received FDA approval in the United States in early 2026 and has an active Marketing Authorization Application filed with the UK's MHRA, with filings underway for additional European territories.

Source: BSE India Corporate Announcements | National Stock Exchange of India | Tenpoint Therapeutics Press Releases